● Recruiting
Phase I
Neurology
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer’s Disease
Drug being tested: DNL921 is a novel investigational agent undergoing Phase 1/1b evaluation for safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and…
20 Aug 2026
NCT07758595